(TBPH) Theravance Biopharma - Ratings and Ratios
YUPELRI, Ampreloxetine, TRELEGY
TBPH EPS (Earnings per Share)
TBPH Revenue
Description: TBPH Theravance Biopharma
Theravance Biopharma Inc is a US-based biopharmaceutical company that focuses on developing and commercializing medicines, particularly for respiratory diseases. The company has a strong portfolio, with its lead product YUPELRI being a once-daily nebulized long-acting muscarine antagonist for the treatment of chronic obstructive pulmonary pulmonary disease (COPD). YUPELRI has shown promise in the market, and the company has a strategic collaboration with Viatis Inc for the development and commercialization of related products.
Theravance Biophpha is also advancing its pipeline with Ampreloxetine, a norepinephrine reuptake inhibitor, which has completed Phase III trials for the treatment of neurogenic orthostatic hypotension, a condition with significant unmet medical need. While the company has a presence in the US market, its financials indicate a substantial investment in R&D, reflected in the negative Return on Equity. The companys stock is publicly traded on NASDAQ under the ticker symbol TBPH.
Analyzing the technical data, we see that the stock has shown a rising trend, with the short-term and medium-term SMAs (SMA20 and SMA50) indicating a positive momentum, and the stock price is currently above these averages. The 52-week high and low suggest a relatively stable price action. The Average True Range (ATR) is 0.40, indicating a moderate level of price volatility. Based on this, a potential trading strategy could be to buy on dips, targeting a price around the 52-week high.
From a fundamental perspective, Theravance Biopharmaceuticals has a market capitalization of $531.51M, and a forward P/E ratio of 526.32, suggesting a high growth expectation. While the negative P/E and ROE may indicate current operational challenges, the companys product pipeline and partnerships, such as the one with Vitas, are potentially significant growth drivers. A forecast based on the technical and fundamental data might suggest a potential price target of $12.50, based on a 10% increase from the current price, driven by the positive momentum and the potential for the company to progress its pipeline and expand its market share. However, this is tempered by the need for the company to demonstrate continued progress on its R&D initiatives and to navigate the competitive landscape of the biopharmaceutical industry effectively.
TBPH Stock Overview
| Market Cap in USD | 720m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2014-05-16 |
TBPH Stock Ratings
| Growth Rating | 44.3% |
| Fundamental | 77.3% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 49.2% |
| Analyst Rating | 3.75 of 5 |
TBPH Dividends
Currently no dividends paidTBPH Growth Ratios
| Growth Correlation 3m | 85.6% |
| Growth Correlation 12m | 77.1% |
| Growth Correlation 5y | -39.6% |
| CAGR 5y | 12.23% |
| CAGR/Max DD 3y | 0.34 |
| CAGR/Mean DD 3y | 0.70 |
| Sharpe Ratio 12m | -0.10 |
| Alpha | 63.85 |
| Beta | 0.590 |
| Volatility | 35.19% |
| Current Volume | 447.5k |
| Average Volume 20d | 488.7k |
| Stop Loss | 13.8 (-4.2%) |
| Signal | 0.55 |
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (13.0m TTM) > 0 and > 6% of Revenue (6% = 4.63m TTM) |
| FCFTA 0.57 (>2.0%) and ΔFCFTA 65.60pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 403.7% (prev 155.4%; Δ 248.3pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.58 (>3.0%) and CFO 245.0m > Net Income 13.0m (YES >=105%, WARN >=100%) |
| Net Debt (-235.5m) to EBITDA (46.1m) ratio: -5.11 <= 3.0 (WARN <= 3.5) |
| Current Ratio 6.70 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (50.7m) change vs 12m ago 4.06% (target <= -2.0% for YES) |
| Gross Margin 98.23% (prev 72.33%; Δ 25.90pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 19.59% (prev 17.13%; Δ 2.46pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 16.54 (EBITDA TTM 46.1m / Interest Expense TTM 2.58m) >= 6 (WARN >= 3) |
Altman Z'' -6.37
| (A) 0.73 = (Total Current Assets 366.3m - Total Current Liabilities 54.6m) / Total Assets 426.0m |
| (B) -2.17 = Retained Earnings (Balance) -924.3m / Total Assets 426.0m |
| warn (B) unusual magnitude: -2.17 — check mapping/units |
| (C) 0.11 = EBIT TTM 42.7m / Avg Total Assets 394.0m |
| (D) -4.59 = Book Value of Equity -924.3m / Total Liabilities 201.2m |
| Total Rating: -6.37 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 77.32
| 1. Piotroski 6.0pt = 1.0 |
| 2. FCF Yield 45.43% = 5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.70 = 2.26 |
| 5. Debt/Ebitda 3.42 = -2.24 |
| 6. ROIC - WACC 10.22% = 12.50 |
| 7. RoE 6.93% = 0.58 |
| 8. Rev. Trend 73.59% = 5.52 |
| 9. EPS Trend 54.12% = 2.71 |
What is the price of TBPH shares?
Over the past week, the price has changed by +3.45%, over one month by +9.51%, over three months by +33.95% and over the past year by +77.34%.
Is Theravance Biopharma a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TBPH is around 15.39 USD . This means that TBPH is currently overvalued and has a potential downside of 6.88%.
Is TBPH a buy, sell or hold?
- Strong Buy: 1
- Buy: 1
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the TBPH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 20 | 38.9% |
| Analysts Target Price | 20 | 38.9% |
| ValueRay Target Price | 16.9 | 17.2% |
Last update: 2025-09-16 04:41
TBPH Fundamental Data Overview
CCE Cash And Equivalents = 338.8m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 59.5833
P/E Forward = 9.434
P/S = 9.328
P/B = 3.2029
P/EG = -0.05
Beta = 0.047
Revenue TTM = 77.2m USD
EBIT TTM = 42.7m USD
EBITDA TTM = 46.1m USD
Long Term Debt = 146.6m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 10.9m USD (from shortTermDebt, last quarter)
Debt = 157.4m USD (Calculated: Short Term 10.9m + Long Term 146.6m)
Net Debt = -235.5m USD (from netDebt column, last quarter)
Enterprise Value = 538.8m USD (720.2m + Debt 157.4m - CCE 338.8m)
Interest Coverage Ratio = 16.54 (Ebit TTM 42.7m / Interest Expense TTM 2.58m)
FCF Yield = 45.43% (FCF TTM 244.8m / Enterprise Value 538.8m)
FCF Margin = 317.0% (FCF TTM 244.8m / Revenue TTM 77.2m)
Net Margin = 16.88% (Net Income TTM 13.0m / Revenue TTM 77.2m)
Gross Margin = 98.23% ((Revenue TTM 77.2m - Cost of Revenue TTM 1.36m) / Revenue TTM)
Tobins Q-Ratio = -0.58 (set to none) (Enterprise Value 538.8m / Book Value Of Equity -924.3m)
Interest Expense / Debt = 0.42% (Interest Expense 663.0k / Debt 157.4m)
Taxrate = 25.09% (18.4m / 73.2m)
NOPAT = 32.0m (EBIT 42.7m * (1 - 25.09%))
Current Ratio = 6.70 (Total Current Assets 366.3m / Total Current Liabilities 54.6m)
Debt / Equity = 0.70 (Debt 157.4m / last Quarter total Stockholder Equity 224.8m)
Debt / EBITDA = 3.42 (Net Debt -235.5m / EBITDA 46.1m)
Debt / FCF = 0.64 (Debt 157.4m / FCF TTM 244.8m)
Total Stockholder Equity = 188.0m (last 4 quarters mean)
RoA = 3.06% (Net Income 13.0m, Total Assets 426.0m )
RoE = 6.93% (Net Income TTM 13.0m / Total Stockholder Equity 188.0m)
RoCE = 12.75% (Ebit 42.7m / (Equity 188.0m + L.T.Debt 146.6m))
RoIC = 16.99% (NOPAT 32.0m / Invested Capital 188.0m)
WACC = 6.78% (E(720.2m)/V(877.6m) * Re(8.19%)) + (D(157.4m)/V(877.6m) * Rd(0.42%) * (1-Tc(0.25)))
Shares Correlation 3-Years: -48.48 | Cagr: -3.55%
Discount Rate = 8.19% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 69.82% ; FCFE base≈244.8m ; Y1≈160.7m ; Y5≈73.5m
Fair Price DCF = 27.99 (DCF Value 1.41b / Shares Outstanding 50.4m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 54.12 | EPS CAGR: 26.25% | SUE: -9.03 | # QB: False
Revenue Correlation: 73.59 | Revenue CAGR: 31.06%
Additional Sources for TBPH Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle